Photocure Investor Hub

Investment highlights

A commercial-stage company focused on bladder cancer

Hexvix®/Cysview® is a product for the detection of bladder cancer:

  • Established position as an innovation leader in the large and underserved bladder cancer treatment market.
  • Treatment guidelines and reimbursement supports market penetration.
  • In excess of USD 40M in global market sales.
  • Specialist salesforce established in the U.S. and Europe with additional potential value in other territories through our partners; Genotests (Chile), Endotherapeutics Group (Australia/New Zealand), and Asieris MediTech Co., Ltd. (China).

Value-building opportunity

  • Large untapped potential for Hexvix®/Cysview® in existing and new market segments/territories.
  • Opportunities following the FDA approval of Cysview® for use with flexible cystoscope.
  • Exploring expansion of bladder cancer portfolio to leverage commercial infrastructure.

Investor news

Latest reports

Event highlights


22nd Annual Society of Urologic Oncology (SUO) Meeting

29 Nov 2022 - 2 Dec 2022


Nordic-American Life Sciences Conference (NALSC)

7 Dec 2022 - 8 Dec


DNB 13th Annual Nordic Healthcare Conference

15 Dec 2022

Analyst coverage

Photocure ASA is followed by the analysts listed below. Please note that any opinions, estimates or forecasts regarding Photocure ASA's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Photocure ASA or its management.

Photocure ASA does not by its reference below or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

ABG Sundal Collier

Erik Cassel
Tel: +46 8 566 286 03

DNB Markets

Patrik Ling
Tel: +46 733 26 37 69


Rickard Anderkrans
Tel: +46 8 701 1995

Norne Securities AS

Tomas Skeivys
Tel: +47 21 95 37 49